Knockdown of circ‐RAD23B inhibits non‐small cell lung cancer progression via the miR‐142‐3p/MAP4K3 axis

por Zhuang, Qingyang, Huang, Zhangzhou, Zhuang, Wu, Hong, Yaping, Huang, Yunjian
Publicado 2022

Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospec...

por Li, Deyu, Huang, Zhangzhou, Zhong, Jiangming, Lin, Li, Zhang, Guifeng, Zhuang, Wu, Liu, Zhenhua
Publicado 2023

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lu...

por Wang, Wenxian, Huang, Zhangzhou, Yu, Zongyang, Zhuang, Wu, Zheng, Weijun, Cai, Zhijian, Shi, Lei, Yu, Xinmin, Lou, Guangyuan, Hong, Wei, Zhang, Yiping, Chen, Ming, Song, Zhengbo
Publicado 2020

The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel

por Zhuang, Wu, Ma, Junxun, Chen, Xudong, Wang, Guoqiang, Lu, Jing, Chen, Yanan, Dong, Hua, Cai, Shangli, Zhang, Yuzi, Zhao, Xiaochen, Zhu, Youcai, Xu, Chunwei, Huang, Yunjian, Huang, Zhangzhou, Zhu, Xiaofeng, Jiang, Hong, Wang, Zhijie
Publicado 2018

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial

por Xu, Qin, Wang, Junjie, Sun, Yang, Lin, Yibin, Liu, Jing, Zhuo, Yanhong, Huang, Zhangzhou, Huang, Songhua, Chen, Ying, Chen, Li, Ke, Meifang, Li, Li, Li, Zirong, Pan, Junping, Song, Yanwen, Liu, Rongqiang, Chen, Chuanben
Publicado 2022